

Improved Incidence of Cardiovascular Disease in Patients With Incident Rheumatoid Arthritis in the 2000s: A Population-based Cohort Study

Elena Myasoedova¹ , John M. Davis III² , Veronique L. Roger³, Sara J. Achenbach⁴, and Cynthia S. Crowson⁵ 

ABSTRACT. *Objective.* To assess trends in incidence of cardiovascular disease (CVD) and mortality following incident CVD events in patients with rheumatoid arthritis (RA) onset in 1980–2009 vs non-RA subjects.

Methods. We studied Olmsted County, Minnesota residents with incident RA (aged > 18 yrs, 1987 American College of Rheumatology criteria met in 1980–2009) and non-RA subjects from the same source population with similar age, sex, and calendar year of index. All subjects were followed until death, migration, or December 31, 2016. Incident CVD events included myocardial infarction and stroke. Patients with CVD before RA incidence/index date were excluded. Cox models were used to compare incident CVD events by decade, adjusting for age, sex, and CVD risk factors.

Results. The study included 905 patients with RA and 904 non-RA subjects. Cumulative incidence of any CVD event was lower in patients with incident RA in the 2000s vs the 1980s. The HR for any incident CVD in the 2000s vs 1980s was 0.53 (95% CI 0.31–0.93). The strength of association attenuated after adjustment for anti-rheumatic medication use (HR 0.64, 95% CI 0.34–1.22). Patients with RA in the 2000s had no excess in CVD over non-RA subjects (HR 0.71, 95% CI 0.42–1.19). Risk of death after a CVD event was somewhat lower in patients with RA after the 1980s with an HR of 0.54 (95% CI 0.33–0.90) in the 1990s vs 1980s and 0.68 (95% CI 0.33–1.41) in the 2000s vs 1980s.

Conclusion. The incidence of major CVD events in RA has declined in recent decades. The gap in CVD occurrence between patients with RA and the general population is closing. Mortality after CVD events in RA may be improving.

Key Indexing Terms: cardiovascular diseases, epidemiology, rheumatoid arthritis

This work was supported by a grant from the National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR46849), National Heart, Lung, and Blood Institute (HL120859), and the National Institute of Aging (R01 AG068192, R01 AG034676). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. EM is supported by the Louis V. Gerstner, Jr. Fund at Vanguard Charitable.

¹E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, and Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic; ²J.M. Davis III, MD, MS, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic; ³V.L. Roger, MD, MPH, Division of Epidemiology, Department of Health Sciences Research, and Division of Circulatory Failure, Department of Cardiovascular Disease, Mayo Clinic; ⁴S.J. Achenbach, MS, Division of Medical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic; ⁵C.S. Crowson, PhD, Division of Rheumatology, Department of Internal Medicine, and Division of Medical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.

The authors declare no conflict of interest relevant to this article.

Address correspondence to Dr. E. Myasoedova, Mayo Clinic College of Medicine and Science, Division of Rheumatology, 200 1st St. SW, Rochester, MN 55905, USA. Email: myasoedova.elena@mayo.edu.

Accepted for publication January 29, 2021.

An excess burden of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) is an established paradigm. Many epidemiologic studies worldwide have reported a 1.5- to 2-fold increased risk of incident CVD events in RA vs the general population.^{1,2,3,4,5} Death from CVD is a leading cause of premature mortality in RA.^{3,6,7} Metaanalyses integrating the findings published over the past 50 years showed a 2-fold excess risk of CVD death in patients with RA vs the general population, and no apparent decrease in CVD mortality in RA was noted up to the mid-2000s.^{8,9}

More recently published population-based studies from Europe, Canada, and our group suggested improving CVD mortality in patients diagnosed with RA after 2000.^{10,11,12,13} Improved control of RA disease activity following early initiation of antirheumatic treatments and the use of biologic disease-modifying antirheumatic drugs (bDMARDs) were discussed as potential contributors to the decrease in CVD mortality in RA.

Decreased incidence of CVD events and decreased mortality after CVD events could both be contributors to the decreased CVD mortality in recent years in patients with RA. However, longitudinal studies on trends in occurrence of CVD events and mortality after CVD events in patients with RA over time and

studies comparing these trends between RA and the general population are scarce.¹⁴

To address this gap in knowledge, we aimed to (1) assess trends in incidence of CVD in patients with incident RA in 1980–2009; (2) compare incidence of CVD in patients with RA vs non-RA subjects with RA incidence/index date in 1980–2009; (3) assess mortality following incident CVD events in patients with RA in 1980–2009; and (4) compare mortality following incident CVD events in patients with RA vs non-RA subjects with RA incidence/index date in 1980–2009.

METHODS

The study included a population-based inception cohort of Olmsted County, Minnesota residents aged ≥ 18 years (1987 American College of Rheumatology [ACR] classification criteria for RA met between January 1, 1980 and December 31, 2009). Patient ascertainment was performed using the Rochester Epidemiology Project, a population-based medical record linkage system with access to the complete (inpatient and outpatient) medical records from all medical providers in the community.^{15,16,17,18} The RA incidence date was defined as the earliest date of fulfillment of ≥ 4 1987 ACR criteria for RA. The comparison cohort included randomly selected Olmsted County residents without RA who were of similar age, sex, and calendar year of index. Each non-RA subject was assigned an index date corresponding to the incidence date of their matched patient with RA. Calendar year of index refers to the year of that index date (e.g., 2010). All subjects were followed through medical record review until death, migration, or December 31, 2016.

Nurse abstractors reviewed medical records for CVD risk factors: age, smoking, hypertension (HTN), diabetes mellitus (DM), and dyslipidemia, using standardized criteria as described previously.¹⁹ Data on RA characteristics including rheumatoid factor (RF), anticyclic citrullinated peptide (anti-CCP) antibodies, erythrocyte sedimentation rate (ESR), radiographic joint erosions/destructive changes, and use of systemic corticosteroids, conventional (c)DMARDs (e.g., methotrexate [MTX], hydroxychloroquine [HCQ], and other cDMARDs), and bDMARDs (e.g., tumor necrosis factor inhibitors [TNFi], anakinra, abatacept, rituximab, and tocilizumab) were collected.

Data on CVD events (i.e., myocardial infarction [MI], including non-ST segment elevation MI [NSTEMI], and stroke [ischemic or hemorrhagic]) were collected throughout the follow-up using standardized diagnostic criteria, including laboratory and electrocardiographic (ECG) criteria for MI, and clinical diagnosis by a neurologist confirmed by imaging for stroke.^{20,21} MIs were adjudicated by a cardiologist (VLR) to ensure there were no alternative causes for ECG changes or elevated biomarkers. Silent MIs were excluded. Information on coronary revascularization procedures (i.e., percutaneous coronary intervention and coronary artery bypass grafting) was collected.

Vital status information was obtained from state and local death certificates as well as the National Death Index Plus. This study was approved by institutional review boards (IRBs) of the Mayo Clinic (IRB #17-002593) and Olmsted Medical Center (IRB #017-omc-17). The need for informed consent was waived. Patients who declined the use of their medical records for research purposes were not included in the study, per Minnesota law.

Statistical methods. Descriptive characteristics (means, percentages, etc.) were used to summarize the data. Comparisons of characteristics between cohorts were performed using chi-square and rank sum tests. MI and stroke were examined separately, and a combined outcome of “any CVD event” defined as first of either MI or stroke was also examined. For patients who experienced both a stroke and an MI, both events were counted in the analyses of the individual events, respectively.

Patients with CVD events before RA incidence/index date were excluded. Cumulative incidence of CVD events adjusted for the competing

risk of death was calculated. Cox models were used to compare CVD events by decade, adjusting for age and sex (Model 1); age, sex, smoking (current and former), obesity, DM, HTN, and dyslipidemia (Model 2); age, sex, and highest ESR in the first year of RA incidence (Model 3); and variables from Model 2 and time-dependent exposure to cDMARDs and bDMARDs (Model 4). With the use of Cox model calculations which occur at each event time, no comparisons between groups are made after the follow-up ends for 1 of the groups, thus shorter length of follow-up in more recent cohorts vs earlier cohorts does not affect the validity of the comparisons. Sensitivity analyses were performed using an outcome of first of either MI or revascularization procedure. Kaplan-Meier methods were used to estimate all-cause mortality following CVD occurrence. Cox models were used to compare all-cause mortality after CVD event by decade adjusting for age, sex, and RA duration. Analyses were performed using SAS version 9.4 (SAS Institute) and R 3.6.2 (R Foundation for Statistical Computing).

RESULTS

Clinical characteristics of patients with and without RA. The study included 905 patients with RA (a total of 12,808 person-yr of follow-up), of whom 201 were incident RA during 1980–89, 299 during 1990–99, and 405 during 2000–09. Patients with RA onset in different decades were similar in their demographics (Table 1). The percentage of current smokers, the highest ESR in the first year of RA, and the use of other cDMARDs in the first year of RA incidence declined, whereas obesity, HTN, dyslipidemia, use of MTX, HCQ, bDMARDs, and corticosteroids increased in patients with more recent RA onset vs those with RA in earlier decades. Time from RA incidence to initiation of the first DMARD declined dramatically over the decades (Table 1).

The comparison population comprised 904 subjects without RA (a total of 13,095 person-yr of follow-up), including 201 non-RA subjects in 1980–89, 299 in 1990–99, and 404 in 2000–9. Apart from lower rates of smoking, HTN, and dyslipidemia in non-RA subjects, there were no significant differences in demographics and CVD risk factors between RA and non-RA subjects overall (Table 1). Non-RA subjects were more likely to have experienced a stroke before RA incidence/index date ($P = 0.02$). Characteristics of patients without previous CVD events (Supplementary Table 1, available from the authors on request) were similar to those for patients with or without underlying CVD events (Table 1).

Risk of CVD events by decade of RA incidence. Figure 1 shows trends in incidence of any CVD event, MI, and stroke by decade of RA incidence. Adjusting for age and sex, the risk of any CVD event in patients with RA in the 2000s was 42% lower than in 1980s (Table 2). The risk of MI was 56% lower in patients with RA in 2000s vs 1980s, whereas risk of stroke was similar in patients with RA across the decades. These results remained consistent after adjustment for age, sex, smoking, obesity, DM, HTN, and dyslipidemia (Table 2). Adjusting for age, sex, and highest ESR during the first year of RA incidence, the results remained similar for MI, but the strength of association for risk of any CVD event in patients with RA onset in 2000s vs 1980s was attenuated. Adjustment for antirheumatic medications use further attenuated the strength of associations (Table 2).

Table 1. Characteristics of study subjects by decade of RA incidence/index.

	RA Cohort				Non-RA Cohort			
	Overall, n = 905	1980–89, n = 201	1990–99, n = 299	2000–09, n = 405	Overall, n = 904	1980–89, n = 201	1990–99, n = 299	2000–09, n = 404
Age, yrs	55.9 (15.6)	57.2 (15.8)	56.2 (15.9)	55.0 (15.4)	55.9 (15.6)	57.3 (15.7)	56.3 (15.8)	55.0 (15.4)
Female sex	621 (69)	137 (68)	197 (66)	287 (71)	620 (69)	137 (68)	197 (66)	286 (71)
CVD risk factors, at incidence/index								
Cigarette smoking, at RA incidence								
Current	189 (21)	67 (33)	60 (20)	62 (15)	158 (17)	52 (26)	40 (13)	66 (16)
Former	303 (33)	55 (27)	115 (38)	133 (33)	254 (28)	48 (24)	94 (31)	112 (28)
Obesity (BMI > 30 kg/m ²), at RA incidence	284 (31)	33 (16)	83 (28)	168 (41)	259 (29)	30 (15)	70 (23)	159 (39)
Hypertension	366 (40)	77 (38)	105 (35)	184 (45)	323 (36)	65 (32)	88 (29)	170 (42)
Diabetes mellitus	97 (11)	22 (11)	24 (8)	51 (13)	80 (9)	15 (7)	18 (6)	47 (12)
Dyslipidemia	512 (57)	82 (41)	172 (58)	258 (64)	456 (50)	63 (31)	147 (49)	246 (61)
CVD events prior to or on RA incidence/index date ^a								
Myocardial infarction	24 (3)	6 (3)	7 (2)	11 (3)	27 (3)	4 (2)	12 (4)	11 (3)
Stroke (ischemic or hemorrhagic)	10 (1)	5 (2)	2 (1)	3 (1)	23 (3)	5 (2)	10 (3)	8 (2)
Revascularization procedures prior to or on RA incidence/index date								
	40 (4)	2 (1)	16 (5)	22 (5)	26 (3)	4 (2)	8 (3)	14 (3)
Yrs from RA diagnosis to last follow-up								
	14.2 (7.9)	18.8 (10.9)	16.5 (6.9)	10.2 (3.8)	14.5 (8.1)	20.3 (11.0)	17.0 (6.5)	9.7 (3.5)
RA disease characteristics								
RF/CCP positivity, at incidence/ index								
	607 (67)	134 (67)	205 (69)	268 (66)	–	–	–	–
Missing	3	2	0	1				
Highest ESR, during the first year of RA incidence, mm/h								
	32.4 (25.7)	38.9 (27.6)	31.5 (25.1)	30.0 (24.8)	–	–	–	–
Missing	34	13	10	11				
Erosions/destructive changes, during the first year of RA incidence								
	243 (27)	51 (25)	75 (25)	117 (29)	–	–	–	–
Antirheumatic medication use, during the first year of RA incidence								
	–	–	–	–	–	–	–	–
Time from RA incidence to initiation of the first DMARD, months,								
median (IQR)	0.7 (0.0–4.4)	4.5 (0.8–23.3)	0.9 (0.1–5.3)	0.3 (0.0–1.6)	–	–	–	–
Methotrexate	323 (36)	4 (2)	83 (28)	236 (58)	–	–	–	–
Hydroxychloroquine	410 (45)	50 (25)	134 (45)	226 (56)	–	–	–	–
Other cDMARD	137 (15)	56 (28)	44 (15)	37 (9)	–	–	–	–
bDMARD	39 (4)	0 (0)	1 (0)	38 (9)	–	–	–	–
Glucocorticoids	510 (56)	51 (25)	179 (60)	280 (69)	–	–	–	–

Values are mean (SD) for continuous characteristics unless otherwise specified, and n (%) for discrete characteristics. ^a Patients with prior CVD events were excluded from analyses of CVD outcomes. Significant differences between the RA and non-RA cohorts overall included smoking status ($P = 0.001$), hypertension ($P = 0.04$), and dyslipidemia ($P = 0.009$). Significant differences between decades among the RA cohort included smoking status, obesity, hypertension, dyslipidemia, ESR, time from RA incidence to initiation of the first DMARD, use of methotrexate, hydroxychloroquine, other cDMARDs, bDMARDs, and glucocorticoids in the first year of RA incidence (all $P < 0.001$, except hypertension with $P = 0.02$). Significant differences between decades among the non-RA cohort included smoking status ($P = 0.006$), obesity ($P < 0.001$), hypertension ($P = 0.001$), diabetes mellitus ($P = 0.03$), and dyslipidemia ($P < 0.001$). bDMARD: biologic DMARD; CCP: cyclic citrullinated peptide; cDMARD: conventional DMARD; CVD: cardiovascular disease; ESR: erythrocyte sedimentation rate; DMARD: disease-modifying antirheumatic drug; RA: rheumatoid arthritis; RF: rheumatoid factor.

When revascularizations were combined with MI, the results were similar to the trends for MI alone (Table 2). Results were similar after adjustment for age, sex, smoking status, obesity, DM, HTN, dyslipidemia, highest ESR, and antirheumatic medication use.

Trends in incident CVD events and coronary revascularizations among patients who were RF-positive and RF-negative

were similar to the RA cohort overall. However, differences in CVD incidence between the decades did not reach statistical significance in either subgroup. For example, the HR for any CVD event in patients who were RF-positive was 0.58 (95% CI 0.31–1.11) for the 2000s vs 1980s, and for patients who were RF-negative, the HR was 0.50 (95% CI 0.19–1.33) for the 2000s vs 1980s, adjusting for age and sex. As anti-CCP testing




Figure 1. Cumulative incidence of CVD events in patients with RA by decade of RA incidence. (A) any event, (B) MI, (C) stroke (ischemic or hemorrhagic). Trends by decades of RA incidence are shown as follows: 1980–1989 (solid line); 1990–1999 (dashed line); 2000–2009 (dotted line). CVD: cardiovascular disease; MI: myocardial infarction; RA: rheumatoid arthritis.

Table 2. Risk of incident CVD and revascularization procedures in RA by decade of RA incidence.

Event Type	Decade	Total ^a (Events)	HR (95% CI) ^b	<i>P</i>	HR (95% CI) ^c	<i>P</i>	HR (95% CI) ^d	<i>P</i>	HR (95% CI) ^e	<i>P</i>
Any CVD event (MI/stroke)	1980–89	191 (48)	Ref	–	Ref	–	Ref	–	Ref	–
	1990–99	291 (47)	0.84 (0.55–1.29)	0.43	0.89 (0.57–1.39)	0.60	0.87 (0.56–1.36)	0.55	1.02 (0.63–1.64)	0.94
	2000–09	392 (25)	0.58 (0.34–0.98)	0.04	0.53 (0.31–0.93)	0.03	0.63 (0.37–1.08)	0.10	0.64 (0.34–1.22)	0.18
MI	1980–89	195 (26)	Ref	–	Ref	–	Ref	–	Ref	–
	1990–99	292 (24)	0.82 (0.45–1.49)	0.51	0.77 (0.41–1.45)	0.43	0.76 (0.41–1.40)	0.38	0.95 (0.48–1.86)	0.87
	2000–09	394 (10)	0.44 (0.20–0.97)	0.04	0.36 (0.16–0.81)	0.01	0.45 (0.20–0.99)	0.046	0.47 (0.18–1.19)	0.11
Stroke (ischemic or hemorrhagic)	1980–89	196 (27)	Ref	–	Ref	–	Ref	–	Ref	–
	1990–99	297 (28)	0.84 (0.48–1.46)	0.53	0.95 (0.53–1.70)	0.86	0.97 (0.54–1.73)	0.91	1.05 (0.57–1.94)	0.87
	2000–09	402 (18)	0.75 (0.38–1.45)	0.38	0.77 (0.38–1.56)	0.47	0.88 (0.44–1.73)	0.70	0.92 (0.41–2.04)	0.83
MI/ revascularization procedure	1980–89	194 (36)	Ref	–	Ref	–	Ref	–	Ref	–
	1990–99	281 (37)	0.83 (0.51–1.33)	0.43	0.82 (0.49–1.34)	0.42	0.81 (0.49–1.32)	0.40	0.99 (0.58–1.71)	0.97
	2000–09	382 (13)	0.36 (0.18–0.70)	0.003	0.30 (0.15–0.59)	< 0.001	0.37 (0.19–0.72)	0.003	0.40 (0.18–0.87)	0.02

^a Excludes patients with events prior to RA incidence/index. ^b Adjusted for age and sex. ^c Adjusted for age, sex, current and former smoking, obesity, DM, HTN, and dyslipidemia. ^d Adjusted for age, sex, and highest ESR. ^e Adjusted for age, sex, current and former smoking, obesity, DM, HTN, dyslipidemia, time-dependent methotrexate, time-dependent hydroxychloroquine, time-dependent other cDMARDs, and time-dependent bDMARDs. bDMARD: biologic DMARD; cDMARD: conventional DMARD; CVD: cardiovascular disease; DM: diabetes mellitus; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; HTN: hypertension; MI: myocardial infarction; RA: rheumatoid arthritis.

was not widely available until the 2000s, analysis comparing multiple decades for anti-CCP positive vs negative patients was not possible. A sensitivity analysis by RF/anti-CCP positivity showed results similar to those by RF-positivity alone.

Risk of CVD events in patients with RA vs non-RA subjects by decade of RA incidence/index. Unlike the > 50% excess risk of any CVD event in patients with RA in the 1980s and 1990s, patients with incident RA in the 2000s had no excess in any CVD events over non-RA subjects, adjusting for age and sex (Table 3). Adjustment for age, sex, smoking, obesity, DM, HTN, and dyslipidemia has attenuated associations for the 1980s and 1990s, while not altering the results for the 2000s. The HR for the incident MI in patients with RA vs non-RA subjects has declined from approximately 1.6 in 1980s and 1990s

to approximately 0.6 in the 2000s, but these associations did not reach statistical significance in either of the adjustment models (Table 3).

For the combined outcome of MI and/or revascularization, the risk was similar in patients with and without RA across the decades of incidence/index, adjusting for age, sex, smoking, obesity, DM, HTN, and dyslipidemia.

Mortality after CVD events by decade of RA incidence/index. The 120 patients with RA and 94 non-RA subjects who developed an incident CVD event following RA incidence/index date were comparable in age at diagnosis of stroke/MI, years since RA incidence/index at CVD event, and smoking status (Table 4). During follow-up (median 3.3 yrs for RA and 4.2 yrs for non-RA), there were 68 deaths in the 1980–89 cohort (41 RA, 27 non-RA),

Table 3. Risk of incident CVD in patients with RA vs non-RA subjects by decade of RA incidence/index.

Decade	Outcome	Total ^a (Event) in RA	Total ^a (Event) in Non-RA	HR (95% CI) ^b	<i>P</i>	HR (95% CI) ^c	<i>P</i>
Any CVD event	1980–1989	191 (48)	192 (38)	1.66 (1.08–2.56)	0.02	1.46 (0.94–2.27)	0.10
	1990–1999	291 (47)	278 (24)	2.08 (1.27–3.40)	0.004	1.91 (1.15–3.18)	0.01
	2000–2009	392 (25)	385 (32)	0.71 (0.42–1.19)	0.19	0.71 (0.42–1.19)	0.20
MI	1980–1989	195 (26)	197 (21)	1.59 (0.89–2.85)	0.12	1.36 (0.74–2.48)	0.32
	1990–1999	292 (24)	287 (16)	1.60 (0.85–3.01)	0.15	1.31 (0.68–2.54)	0.42
	2000–2009	394 (10)	393 (16)	0.58 (0.26–1.28)	0.18	0.57 (0.26–1.27)	0.17
Stroke (ischemic or hemorrhagic)	1980–1989	196 (27)	196 (23)	1.51 (0.86–2.65)	0.15	1.29 (0.72–2.29)	0.40
	1990–1999	297 (28)	289 (14)	2.27 (1.19–4.32)	0.01	2.25 (1.16–4.34)	0.02
	2000–2009	402 (18)	396 (22)	0.78 (0.42–1.45)	0.43	0.79 (0.42–1.48)	0.46
MI/revascularization	1980–1989	194 (36)	194 (31)	1.37 (0.85–2.23)	0.20	1.10 (0.67–1.81)	0.71
	1990–1999	281 (37)	284 (20)	2.09 (1.21–3.60)	0.008	1.64 (0.94–2.87)	0.08
	2000–2009	382 (13)	388 (20)	0.62 (0.31–1.25)	0.18	0.62 (0.31–1.26)	0.19

^a Excludes patients with events prior to RA incidence/index. ^b Adjusted for age and sex. ^c Adjusted for age, sex, current and former smoking, obesity, diabetes mellitus, hypertension, and dyslipidemia. CVD: cardiovascular disease; MI: myocardial infarction; RA: rheumatoid arthritis.

Table 4: Characteristics of patients with incident CVD events during the follow-up, by decade of RA incidence/index.

	Overall, n = 120	RA Cohort			Overall, N = 94	Non-RA		
		1980–89, n = 48	1990–99, n = 47	2000–09, n = 25		1980–89, n = 38	1990–99, n = 24	2000–09, n = 32
Age, yrs, at MI/ stroke	75.2 (12.0)	76.7 (10.1)	75.0 (13.4)	72.7 (12.6)	75.4 (11.9)	77.1 (10.8)	73.7 (13.3)	74.6 (12.3)
Female sex	71 (59)	32 (67)	26 (55)	13 (52)	62 (66)	25 (66)	15 (63)	22 (69)
Years from RA/ index to MI /stroke	11.1 (8.3)	14.8 (9.8)	10.1 (6.4)	5.8 (3.8)	10.6 (7.5)	14.5 (8.9)	10.3 (5.2)	6.2 (3.9)
RF/CCP-positive	86 (72)	32 (67)	36 (77)	18 (72)	–	–	–	–
Ever smoker	75 (63)	33 (69)	29 (62)	13 (52)	51 (54)	20 (53)	16 (67)	15 (47)
Years from MI/stroke to last follow-up, median (IQR)	3.3 (0.6–7.2)	2.0 (0.1–6.7)	4.7 (2.3–8.8)	3.5 (0.2–6.1)	4.2 (0.5–8.2)	3.4 (0.1–8.9)	5.2 (1.3–8.1)	4.1 (1.1–6.7)

Values are mean (SD) for continuous characteristics unless otherwise specified, and N (%) for discrete characteristics. There were no significant differences in characteristics of the RA and non-RA cohorts overall or by decade of RA incidence/index. Significant differences between decades among the RA cohort and among the non-RA cohort included years from RA/index date to MI/stroke (both *P* < 0.001). CCP: cyclic citrullinated peptide; CVD: cardiovascular disease; MI: myocardial infarction; RA: rheumatoid arthritis; RF: rheumatoid factor.

45 deaths in the 1990–99 cohort (30 RA, 15 non-RA), and 26 deaths in the 2000–09 cohort (12 RA, 14 non-RA).

Among patients with RA with incident CVD events, mortality was somewhat lower, particularly in patients with RA onset in 1990s (HR 0.54, 95% CI 0.33–0.90), while not reaching statistical significance for patients with RA onset in 2000s (HR 0.68, 95% CI 0.33–1.41) compared to the 1980s, adjusting for age, sex, and RA duration. Figure 2 shows mortality following incident CVD event in RA by decade of RA incidence.

Among patients with incident CVD, mortality was similar between patients with RA and non-RA subjects with incidence/index date in 1980–89 (HR 1.38, 95% CI 0.84–2.27), 1990–99 (HR 1.18, 95% CI 0.62–2.23), and 2000–09 (HR 1.87, 95% CI 0.82–4.26), adjusting for age, sex, and years since RA incidence/index.

DISCUSSION

This study shows a decrease in the incidence of major CVD

events in successive population-based incident RA cohorts. This improvement appears to be largely driven by a > 50% decline in the incidence of MI in patients with RA onset in the 2000s vs 1980s, concomitant with the declining incidence of MI in the general population.²²

Coronary artery disease (CAD) is an established contributor to excess CVD risk and mortality in RA.^{3,6,23} A metaanalysis of observational studies estimated a 68% increase in the risk of acute MI in patients with RA vs the general population (pooled relative risk 1.68, 95% CI 1.40–2.03), with significantly increased risk in both sexes.¹ This is consistent with our estimates of an approximately 60% increase in risk of MI in patients with RA onset in the 1980s and 1990s vs the non-RA subjects. While not reaching statistical significance in any of the decades, one may appreciate reversal of the risk estimate for incident MI in RA vs non-RA subjects from approximately 1.6 in the 1980s and 1990s to approximately 0.6 in the 2000s. Taken together with the statistically significant decline in the risk of incident




Figure 2. Mortality following an incident CVD event in patients with RA by decade of RA incidence. Trends by decade of RA incidence are shown as follows: 1980–1989 (solid line), 1990–1999 (dashed line), 2000–2009 (dotted line). CVD: cardiovascular disease; MI: myocardial infarction; RA: rheumatoid arthritis.

MI in RA in the 2000s vs 1980s, this suggests that the rate of improvement in MI risk in RA may be outpacing that of the general population. While data on trends in incidence of CVD events in RA are scarce, a recent nationwide cohort study from Sweden showed an approximately 40% decline in the incidence of acute coronary syndrome (ACS) in the general population and in patients with RA.¹⁴ Unlike in patients with new-onset RA in the late 1990s and 2000s, who persistently had an approximately 40% excess risk of ACS compared to the general population, the HR for ACS was not statistically significant (1.19, 95% CI 0.85–1.67) in patients with new-onset RA in 2011–2014, potentially suggesting an emerging decrease in excess ACS risk in RA. Preliminary findings from a British Columbia population have suggested a decreased risk of incident MI in patients diagnosed with RA in 1997–2004 and followed up through 2014, and a parallel decline in the risk of MI in matched comparators from the general population.²⁴ Our study extends these studies by reporting results from successive incidence RA cohorts in a geographically different population and strengthens the evidence of declining MI incidence in patients with RA in recent years.

Coronary revascularization procedures are increasingly widespread therapeutic interventions for patients with CAD with a potential effect on subsequent CVD events.^{25,26} The trends by decade of RA incidence for the combined outcome of MI or revascularization were similar to the trends for MI alone.

Unlike the improving incidence of MI, in this study, no statistically significant differences in the risk of ischemic or hemorrhagic stroke by decade of RA incidence or by RA status were found. Reasons for this lack of improvement are not immediately apparent from our observational study. The association between RA and risk of stroke is weaker and less consistent across studies, compared to the well-established association between RA and risk of MI.¹ A difference in the pathogenesis of cerebrovascular disease vs CAD (i.e., potentially longer time to occurrence of cerebrovascular events compared to coronary events), stemming from differences in the anatomy and physiology of

cerebrovascular and cardiovascular beds, has been suggested as a potential explanation for differences in strength of association between RA and stroke vs RA and MI.^{27,28,29} Similar reasoning may relate to our finding of lack of significant decline in the incidence of stroke. However, other explanations (e.g., population-specific environmental effects and difference in effect of preventive practices for MI and stroke) should be considered. There is emerging evidence of decline in incidence of ischemic stroke in the population of British Columbia after 1999.³⁰ These findings, based on trends in ischemic stroke by cohort year 1997–2004, are not directly comparable to ours based on trends in ischemic and hemorrhagic stroke by decade of RA incidence/index (1980–2000). Further studies evaluating trends in the incidence of stroke in RA are warranted.

While earlier observational studies from different populations have reported increased mortality after acute MI in patients with RA vs non-RA subjects, including 30-day and 1-year mortality,^{31,32,33} a recent National Inpatient Sample database analysis showed no increase in in-hospital mortality following acute MI in patients with RA in 2005–2014.³⁴ In our study, mortality following incident MI and/or stroke showed potential improvement in patients with RA diagnosed after 1980s, whereas relative mortality was similar in patients with RA and non-RA subjects across the decades of the study.

What are the reasons for the improved CVD incidence in RA? The reasons are likely several-fold. Improvement in CVD health in patients with RA onset in recent decades may reflect improvement in CVD morbidity and mortality in the general population following implementation of effective CVD prevention and management strategies. We observed some improvement in the CVD risk factor profile in patients with RA across the decades of study. While smoking and dyslipidemia were more prevalent in RA vs non-RA in earlier decades, prevalence of these and other major CVD risk factors (i.e., obesity, DM, and HTN) was similar in patients with RA vs non-RA subjects with incidence/index dates in the 2000s. Measures for improved awareness and timely management of CVD risk factors in patients with RA (i.e., increase in statin prescribing and diagnosis of HTN) may

be contributing to the improving CVD risk factor profile and declining CVD incidence in RA.^{35,36}

The improved incidence of CVD events in RA vs non-RA implies a closing gap in CVD occurrence between RA and the general population, and suggests RA-specific reasons for these trends. The pivotal role of inflammation in the pathogenesis of CVD has been shown both in RA and the general population, with a dose-response relationship between chronicity and severity of inflammation and the acuity and severity of CVD outcomes.^{14,37,38,39,40,41,42,43} Implementation of treat-to-target strategies, early initiation of DMARDs, and the rapidly increasing use of bDMARDs have revolutionized rheumatology care, leading to substantial outcome improvement in RA, including CVD outcome improvement, which is largely attributable to improved control of systemic inflammation.^{44,45} A systematic review and metaanalysis of observational studies and randomized controlled trials showed a 28% reduction in CVD events in patients with RA on MTX and a 30% reduction with TNFi.⁴⁵ In our study, the use of MTX and bDMARDs has increased in patients with more recent RA onset, whereas time from RA incidence to initiation of the first DMARD has drastically declined over the decades. These therapeutic changes were accompanied by a decline in the highest ESR in the first year of RA over the decades of RA incidence, suggesting that improved control of RA disease activity can be contributing to the observed improvement in incidence of CVD events in RA.

This study has a number of important implications. The major decline in the incidence of CVD events in RA and equilibration of CVD incidence between RA and the general population, augmenting the previously reported decline in CVD mortality in patients with RA, suggests an emerging paradigm shift from the well-established concept of substantially increased CVD incidence and CVD mortality in RA. It can be hypothesized that the decrease in incidence of acute MI as the major driver for the improved incidence of CVD events overall in patients with RA is a likely contributor to improved CVD mortality in RA over time. Both improved control of inflammation and increasing efforts for optimization of CVD risk management in RA in recent years could be important contributors to these trends, particularly to the closing gap in CVD occurrence in RA vs non-RA subjects. Future studies aimed at understanding the underlying nature for these trends, together with studies evaluating trends in noncardiac peripheral vascular disease, may aid in improving CVD risk management strategies in patients with rheumatic diseases as well as in the general population.

There are some potential limitations to this study. There is a chance for miscoding of the CVD events. However, this would affect all subjects in the study and thus is unlikely to significantly bias the comparisons. In an unlikely possibility that NSTEMI events were missed in the earlier decades due to less sensitive diagnostic assays compared to the 2000s, this would be expected to comparably affect both the RA and non-RA cohorts and no differential misclassification bias would be expected. Patients with chronic inflammatory conditions other than RA were not excluded from either the RA or the non-RA cohort to minimize

selection bias. Applying this inclusion criterion to both cohorts likely minimizes any differential effect of these conditions on the comparisons. The reasons for the emerging improvement in mortality following CVD events in RA warrant further study. During the period of investigation, the population of Olmsted County, Minnesota was predominantly White. Thus, the results should be replicated in different populations.

This study has several important strengths. Our study takes advantage of its population-based design and use of a comprehensive medical record linkage system including all inpatient and outpatient care from all local providers. Standardized case ascertainment and inclusion of successive incidence cohorts strengthen the study. Our study also takes advantage of the long and complete follow-up of all subjects and the availability of a non-RA comparison cohort from the same underlying population. Use of uniform classification of CVD events and available data on CVD risk factors for both cohorts, as well as data on RA characteristics and medications also strengthens the study.

In conclusion, following decades of increased CVD risk in RA, a reduction in incidence of major CVD events was found. The reduction was primarily in acute MI and was not explained by earlier revascularization interventions. The gap in CVD occurrence between patients with RA and the general population is closing. There was also some improvement in mortality following CVD events in RA in recent decades. Taken collectively, these findings highlight an important milestone in CVD management, opening grounds for investigation of the reasons for these trends, with implications for patients with rheumatic diseases and beyond.

REFERENCES

1. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Ann Rheum Dis* 2012;71:1524-9.
2. Holmqvist ME, Wedrén S, Jacobsson LT, Klareskog L, Nyberg F, Rantapää-Dahlqvist S, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. *J Intern Med* 2010;268:578-85.
3. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum* 2005;52:402-11.
4. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. *Arthritis Rheum* 2009;61:1571-9.
5. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. *Arthritis Rheum* 2008;58:2612-21.
6. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. *Ann Rheum Dis* 2006;65:1608-12.
7. Sparks JA, Chang SC, Liao KP, Lu B, Fine AR, Solomon DH, et al. Rheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the Nurses' Health Study. *Arthritis Care Res* 2016;68:753-62.
8. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with

- rheumatoid arthritis: a meta-analysis of observational studies. *Arthritis Rheum* 2008;59:1690-7.
9. Meune C, Touzé E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. *Rheumatology* 2009;48:1309-13.
 10. Myasoedova E, Gabriel SE, Matteson EL, Davis JM III, Thorneau TM, Crowson CS. Decreased cardiovascular mortality in patients with incident rheumatoid arthritis (RA) in recent years: dawn of a new era in cardiovascular disease in RA? *J Rheumatol* 2017; 44:732-9.
 11. Kerola AM, Nieminen TV, Virta LJ, Kautiainen H, Kerola T, Pohjolainen T, et al. No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000–2008. *Clin Exp Rheumatol* 2015;33:391-8.
 12. Lacaille D, Avina-Zubieta JA, Sayre EC, Abrahamowicz M. Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population—closing the mortality gap. *Ann Rheum Dis* 2017;76:1057-63.
 13. Provan SA, Lillegraven S, Sexton J, Angel K, Austad C, Haavardsholm EA, et al. Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study. *Rheumatology* 2020; 59:505-12.
 14. Holmqvist M, Ljung L, Askling J. Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks. *Ann Rheum Dis* 2017;76:1642-7.
 15. Kremers HM, Myasoedova E, Crowson CS, Savova G, Gabriel SE, Matteson EL. The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases. *Rheumatology* 2011;50:6-15.
 16. Maradit Kremers H, Crowson CS, Gabriel SE. Rochester Epidemiology Project: a unique resource for research in the rheumatic diseases. *Rheum Dis Clin North Am* 2004;30:819-34, vii.
 17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
 18. Myasoedova E, Crowson CS, Maradit Kremers H, Thorneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. *Arthritis Rheum* 2010;62:1576-82.
 19. Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, Davis JM 3rd, Roger VL, et al. The influence of rheumatoid arthritis disease characteristics on heart failure. *J Rheumatol* 2011;38: 1601-6.
 20. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. *Am Heart J* 1984;108:150-8.
 21. Prineas R, Crow R, Blackburn H. Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. Littleton: Wright-PSG; 1982.
 22. Raphael CE, Roger VL, Sandoval Y, Singh M, Bell M, Lerman A, et al. Incidence, trends, and outcomes of type 2 myocardial infarction in a community cohort. *Circulation* 2020;141:454-63.
 23. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. *Ann Rheum Dis* 2011;70:929-34.
 24. Yazdani K, Xie H, Avina A, Zheng Y, Abrahamowicz M, Lacaille D. Secular trends in the incident risk of acute myocardial infarction in rheumatoid arthritis relative to the general population [abstract]. *Ann Rheum Dis* 2019;78:328-9.
 25. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2019;40:87-165.
 26. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)—executive summary: a report of the American College of Cardiology/ American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. *Circulation* 2001;103:3019-41.
 27. Avina-Zubieta JA, Abrahamowicz M, Choi HK, Rahman MM, Sylvestre MP, Esdaile JM, et al. Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: a population-based study. *Ann Rheum Dis* 2011;70:990-5.
 28. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. *Expert Opin Pharmacother* 2008; 9:1121-8.
 29. Meune C, Touzé E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. *Arch Cardiovasc Dis* 2010;103:253-61.
 30. Yazdani K, Xie H, Avina A, Zheng YF, Abrahamowicz M, Lacaille D. Secular trends in the incident risk of cerebrovascular accident in rheumatoid arthritis relative to the general population [abstract]. *Ann Rheum Dis* 2019;78:120.
 31. Van Doornum S, Bohensky M, Tacey MA, Brand CA, Sundararajan V, Wicks IP. Increased 30-day and 1-year mortality rates and lower coronary revascularisation rates following acute myocardial infarction in patients with autoimmune rheumatic disease. *Arthritis Res Ther* 2015;17:38.
 32. Skielta M, Soderstrom L, Rantapaa-Dahlqvist S, Jonsson SW, Moee T. Trends in mortality, co-morbidity and treatment after acute myocardial infarction in patients with rheumatoid arthritis 1998-2013. *Eur Heart J Acute Cardiovasc Care* 2020;9:931-38.
 33. Lai CH, Hsieh CY, Barnado A, Huang LC, Chen SC, Tsai LM, et al. Outcomes of acute cardiovascular events in rheumatoid arthritis and systemic lupus erythematosus: a population-based study. *Rheumatology* 2020;59:1355-63.
 34. Bandyopadhyay D, Banerjee U, Hajra A, Chakraborty S, Amgai B, Ghosh RK, et al. Trends of cardiac complications in patients with rheumatoid arthritis: analysis of the United States National Inpatient Sample; 2005-2014. *Curr Probl Cardiol* 2021;46:100455.
 35. Persell SD, Lee JY, Lipiszko D, Pehrah YA, Ruderman EM, Schachter M, et al. Outreach to promote management of cardiovascular risk in primary care among patients with rheumatoid arthritis seen in rheumatology practice. *ACR Open Rheumatol* 2020;2:131-7.
 36. Burggraaf B, van Breukelen-van der Stoep DF, de Vries MA, Klop B, Liem AH, van de Geijn GM, et al. Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. *Ann Rheum Dis* 2019;78:335-41.
 37. Myasoedova E, Chandran A, Ilhan B, Major BT, Michet CJ, Matteson EL, et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. *Ann Rheum Dis* 2016;75:560-5.
 38. Myasoedova E, Crowson CS, Maradit Kremers H, Roger VL, Fitz-Gibbon PD, Thorneau TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. *Ann Rheum Dis* 2011;70:482-7.

39. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium; Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet* 2012;379:1214-24.
40. Avouac J, Meune C, Chenevier-Gobeaux C, Dieudé P, Borderie D, Lefevre G, et al. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. *J Rheumatol* 2014;41:248-55.
41. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. *Am J Med* 2008;121 Suppl 1:21-31.
42. Arts EE, Fransen J, Den Broeder AA, van Riel PL, Popa CD. Low disease activity ($DAS28 \leq 3.2$) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. *Ann Rheum Dis* 2017;76:1693-9.
43. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. *Arthritis Rheumatol* 2015;67:1449-55.
44. Nurmohamed MT. Editorial: treat to target in rheumatoid arthritis: good for the joints as well as the heart? *Arthritis Rheumatol* 2015;67:1412-5.
45. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *Ann Rheum Dis* 2015;74:480-9.